Healios K.K. (OTCMKTS:HLOSF) Short Interest Update

Healios K.K. (OTCMKTS:HLOSF) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 62,900 shares, a growth of 24.6% from the October 15th total of 50,500 shares. Based on an average trading volume of 3,700 shares, the short-interest ratio is presently 17.0 days.

Healios K.K. Stock Performance

Healios K.K. stock remained flat at 1.50 during mid-day trading on Friday. Healios K.K. has a 1-year low of 0.93 and a 1-year high of 1.73. The business has a 50 day moving average of 1.62 and a two-hundred day moving average of 1.32.

Healios K.K. Company Profile

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease.